Analyst firms · Barclays · OSCR
Barclays OSCR price target and rating history
Oscar Health Inc. (OSCR) · Health Care
Barclays rates Oscar Health Inc. (OSCR) Overweight with a $35 price target, as of its latest action on Jun 10, 2026. It has published 3 rating actions on OSCR since July 2025, including 2 upgrades and 0 downgrades. Across 7 firms with a OSCR price target in the last 12 months, the median target is $18. Barclays's $35 is 94% above that.
- Current rating
- Overweight
- Price target
- $35
- Median target, all firms
- $18
- Actions on OSCR
- 3
Barclays price target on OSCR
Every Barclays rating on OSCR
- Jun 10, 2026
- Jan 5, 2026
- Jul 2, 2025
How other firms rate OSCR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Barclays | Overweight | $35 | Jun 10, 2026 |
| Wells Fargo | Equal Weight | $20 | Jun 4, 2026 |
| Wolfe Research | Peer Perform | May 6, 2026 | |
| Jefferies | Hold | $16 | Apr 20, 2026 |
| Raymond James | Outperform | $18 | Feb 12, 2026 |
| UBS | Neutral | $17 | Jan 9, 2026 |
| Stephens | Equal-Weight | $17 | Dec 11, 2025 |
| Piper Sandler | Overweight | $25 | Nov 26, 2025 |
Questions about Barclays and OSCR
- What is Barclays's price target for OSCR?
- Barclays's latest stated price target for Oscar Health Inc. (OSCR) is $35, from its action on Jun 10, 2026.
- What is Barclays's rating on OSCR?
- Barclays rates OSCR Overweight, a bullish rating, as of Jun 10, 2026.
- When did Barclays last change its view on OSCR?
- On Jun 10, 2026, Barclays upgrades to Overweight from Equal Weight, price target $35.
- How does Barclays's OSCR target compare with other analysts?
- Across 7 firms with a OSCR price target in the last 12 months, the median target is $18. Barclays's $35 is 94% above that.
More OSCR rating histories
All Barclays ratingsOSCR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.